Perigon Wealth Management, LLC Clovis Oncology, Inc. Transaction History

Perigon Wealth Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Dec 13, 2022	SELL	$1.05 - $2.85 $501 - $1,362	-478 Reduced 0.78%	61,093 $73,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $50,050 - $109,900	35,000 Added 131.72%	61,571 $124,000
Q4 2021 Feb 11, 2022	BUY	$2.7 - $4.76 $2,160 - $3,808	800 Added 3.1%	26,571 $72,000
Q3 2021 Nov 01, 2021	BUY	$4.06 - $5.8 $104,630 - $149,471	25,771 New	25,771 $115,000
Q3 2021 Oct 25, 2021	SELL	$4.06 - $5.8 $104,630 - $149,471	-25,771 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$5.02 - $7.05 $3,870 - $5,435	771 Added 3.08%	25,771 $149,000
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $120,249 - $258,500	25,000 New	25,000 $176,000
Q2 2018 Aug 07, 2018	SELL	$42.06 - $62.4 $30,619 - $45,427	-728 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $1,503 - $2,031	30 Added 4.3%	728 $38,000
Q3 2017 Dec 05, 2017	BUY	$67.17 - $84.81 $46,884 - $59,197	698 New	698 $58,000
Q3 2011 Nov 14, 2022	SELL	N/A	-478	61,093 $73,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Perigon Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Perigon Wealth Management, LLC with notifications on news.